JP2013518893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518893A5 JP2013518893A5 JP2012552071A JP2012552071A JP2013518893A5 JP 2013518893 A5 JP2013518893 A5 JP 2013518893A5 JP 2012552071 A JP2012552071 A JP 2012552071A JP 2012552071 A JP2012552071 A JP 2012552071A JP 2013518893 A5 JP2013518893 A5 JP 2013518893A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- concentration
- avpal variant
- subject
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 42
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 25
- 238000000034 method Methods 0.000 claims 23
- 229960005190 phenylalanine Drugs 0.000 claims 18
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 15
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 10
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 10
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 7
- 201000011252 Phenylketonuria Diseases 0.000 claims 6
- 238000005349 anion exchange Methods 0.000 claims 6
- 239000013592 cell lysate Substances 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 235000005911 diet Nutrition 0.000 claims 5
- 230000037213 diet Effects 0.000 claims 5
- 210000002381 plasma Anatomy 0.000 claims 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 238000000108 ultra-filtration Methods 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 230000008014 freezing Effects 0.000 claims 4
- 238000007710 freezing Methods 0.000 claims 4
- 239000006228 supernatant Substances 0.000 claims 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 3
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 238000011026 diafiltration Methods 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- 238000010257 thawing Methods 0.000 claims 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 claims 3
- 102220537984 Clavesin-1_S110C_mutation Human genes 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 102200021562 c.1117G>A Human genes 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003599 detergent Substances 0.000 claims 2
- 239000012538 diafiltration buffer Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 230000002934 lysing effect Effects 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- 102200000387 rs121917857 Human genes 0.000 claims 2
- 102200057376 rs1553135971 Human genes 0.000 claims 2
- 102220034979 rs199475615 Human genes 0.000 claims 2
- 102200027736 rs5030841 Human genes 0.000 claims 2
- 102200031316 rs5030849 Human genes 0.000 claims 2
- 102200031487 rs5030853 Human genes 0.000 claims 2
- 102200031113 rs5030856 Human genes 0.000 claims 2
- 102200031139 rs5030860 Human genes 0.000 claims 2
- 102200031429 rs62514931 Human genes 0.000 claims 2
- 102200031124 rs62516101 Human genes 0.000 claims 2
- 102200031116 rs62516103 Human genes 0.000 claims 2
- 102220034971 rs62642095 Human genes 0.000 claims 2
- 102200027738 rs62642926 Human genes 0.000 claims 2
- 102200027873 rs62642929 Human genes 0.000 claims 2
- 102200031143 rs62644465 Human genes 0.000 claims 2
- 102200027763 rs75193786 Human genes 0.000 claims 2
- 102200027764 rs76394784 Human genes 0.000 claims 2
- 102200031444 rs76687508 Human genes 0.000 claims 2
- 102200031393 rs77958223 Human genes 0.000 claims 2
- 102200094634 rs80356692 Human genes 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30147810P | 2010-02-04 | 2010-02-04 | |
| US61/301,478 | 2010-02-04 | ||
| PCT/US2011/023534 WO2011097335A2 (en) | 2010-02-04 | 2011-02-03 | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518893A JP2013518893A (ja) | 2013-05-23 |
| JP2013518893A5 true JP2013518893A5 (https=) | 2014-03-20 |
| JP5828844B2 JP5828844B2 (ja) | 2015-12-09 |
Family
ID=44356065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552071A Active JP5828844B2 (ja) | 2010-02-04 | 2011-02-03 | 原核生物フェニルアラニンアンモニアリアーゼ変異体の組成物、及び、その組成物を用いる方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20130039898A1 (https=) |
| EP (4) | EP4062928A3 (https=) |
| JP (1) | JP5828844B2 (https=) |
| CN (2) | CN106834261B (https=) |
| AU (1) | AU2011212929B2 (https=) |
| CA (1) | CA2782444C (https=) |
| CY (1) | CY1120768T1 (https=) |
| DK (1) | DK3025728T3 (https=) |
| ES (2) | ES2582459T3 (https=) |
| HK (1) | HK1225299B (https=) |
| HR (1) | HRP20181602T1 (https=) |
| HU (1) | HUE039516T2 (https=) |
| IL (2) | IL221099B (https=) |
| LT (1) | LT3025728T (https=) |
| PL (1) | PL3025728T3 (https=) |
| PT (1) | PT3025728T (https=) |
| SI (1) | SI3025728T1 (https=) |
| WO (1) | WO2011097335A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319601D0 (en) † | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| ES2582459T3 (es) | 2010-02-04 | 2016-09-13 | Biomarin Pharmaceutical Inc. | Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones |
| KR102218930B1 (ko) | 2013-04-18 | 2021-02-23 | 코덱시스, 인코포레이티드 | 조작된 페닐알라닌 암모니아 리아제 폴리펩티드 |
| WO2015161019A1 (en) | 2014-04-16 | 2015-10-22 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| TWI743023B (zh) | 2014-05-21 | 2021-10-21 | 日商Ｋｍ生物醫藥股份有限公司 | 基質金屬蛋白酶 7(mmp-7)聚集體之單體化方法 |
| FI3237621T3 (fi) | 2014-12-22 | 2023-06-01 | Codexis Inc | Ihmisen alfa-galaktosidaasivariantteja |
| CA2972638C (en) | 2015-01-09 | 2023-11-28 | Mcmaster University | Allosteric activators for treatment of phenylketonuria, and method for identifying allosteric activators |
| CN106636048A (zh) * | 2016-12-14 | 2017-05-10 | 江南大学 | 一株酶活提高的苯丙氨酸脱氨酶突变体 |
| AU2018217495B2 (en) | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CN108424897B (zh) * | 2018-03-13 | 2020-08-14 | 广州铭康生物工程有限公司 | 一种rhTNK-tPA细胞收获液的纯化方法 |
| CN108315338A (zh) * | 2018-04-18 | 2018-07-24 | 山东省果树研究所 | 一种石榴苯丙氨酸解氨酶pal及其表达基因与应用 |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| SG11202105668PA (en) | 2018-12-14 | 2021-06-29 | Codexis Inc | Engineered tyrosine ammonia lyase |
| SG11202106348QA (en) | 2018-12-20 | 2021-07-29 | Codexis Inc | Human alpha-galactosidase variants |
| EP4501403A3 (en) | 2019-08-30 | 2025-05-14 | Société des Produits Nestlé S.A. | Engineered lipase variants |
| KR20220129547A (ko) | 2019-12-20 | 2022-09-23 | 코덱시스, 인코포레이티드 | 조작된 산성 알파-글루코시다제 변이체 |
| WO2021158686A1 (en) | 2020-02-04 | 2021-08-12 | Codexis, Inc. | Engineered leucine decarboxylases |
| US20230183712A1 (en) * | 2020-02-19 | 2023-06-15 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| CN115298308A (zh) * | 2020-03-20 | 2022-11-04 | 同生运营公司 | 经工程化以减轻高苯丙氨酸血症的微生物 |
| MX2023002421A (es) | 2020-08-28 | 2023-05-18 | Codexis Inc | Variantes de amilasa modificadas geneticamente. |
| EP4204554A4 (en) | 2020-08-28 | 2024-08-21 | Codexis, Inc. | MODIFIED PROTEASE VARIANTS |
| CN112662606A (zh) * | 2021-01-06 | 2021-04-16 | 中国科学院分子植物科学卓越创新中心 | 用于治疗苯丙酮尿症的工程益生菌 |
| JP2024519847A (ja) | 2021-05-19 | 2024-05-21 | ビオマリン プハルマセウトイカル インコーポレイテッド | 原核生物フェニルアラニンアンモニアリアーゼの組成物及び青年対象を治療する方法 |
| CN118475692A (zh) | 2021-11-01 | 2024-08-09 | 森蒂斯生物公司 | 工程化亮氨酸脱羧酶 |
| WO2024032012A1 (zh) * | 2022-08-10 | 2024-02-15 | 百葵锐(深圳)生物科技有限公司 | 苯丙氨酸解氨酶突变体及其应用 |
| CN116218828A (zh) * | 2022-12-30 | 2023-06-06 | 苏州普瑞森生物科技有限公司 | 一种苯丙氨酸解氨酶、编码基因及其应用 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| US20250108095A1 (en) * | 2023-09-28 | 2025-04-03 | Aperiam Bio, Inc. | Degradation of toxins in vivo |
| WO2025106759A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| DE3581238D1 (de) | 1984-07-05 | 1991-02-14 | Mitsubishi Chem Ind | Mikrobiologische herstellung von l-phenylalanin. |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5466781A (en) * | 1991-05-24 | 1995-11-14 | Chiron Therapeutics | Process for purifying bacterially produced M-CSF |
| US5690929A (en) | 1992-11-19 | 1997-11-25 | Anticancer, Inc. | Use of methioninase and chemotherapy agents in chemotherapy |
| DE69233695T2 (de) | 1992-12-04 | 2008-01-24 | Me Medical Enzymes Ag | Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie |
| DK75593D0 (https=) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| CA2230492C (en) | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| IL138990A0 (en) | 1999-02-12 | 2001-11-25 | Biostream Inc | Matrices for drug delivery and methods for making and using the same |
| US6596849B1 (en) | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| AU2001257032A1 (en) | 2000-04-14 | 2001-10-30 | University Of South Carolina Research Foundation | Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US20030017504A1 (en) | 2001-05-21 | 2003-01-23 | Shearwater Corporation | Antibodies specific for poly(ethylene glycol) |
| US6939941B2 (en) | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| EP1476563B1 (en) | 2002-02-26 | 2008-09-17 | E.I. Du Pont De Nemours And Company | Method for the recombination of genetic elements |
| BR0314356A (pt) * | 2002-09-16 | 2005-07-19 | Wyeth Corp | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas |
| US20080124275A1 (en) | 2002-11-14 | 2008-05-29 | The Scripps Research Institute | Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
| US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| RU2385878C2 (ru) * | 2004-02-11 | 2010-04-10 | Амилин Фармасьютикалз, Инк. | Пептид, обладающий свойствами амилина (варианты), и его применение (варианты) |
| US7553653B2 (en) | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US20090011400A1 (en) | 2006-12-01 | 2009-01-08 | The Salk Institute for Biological Studies and The Regents of the University of California | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| ES2582459T3 (es) | 2010-02-04 | 2016-09-13 | Biomarin Pharmaceutical Inc. | Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones |
-
2011
- 2011-02-03 ES ES11740323.8T patent/ES2582459T3/es active Active
- 2011-02-03 EP EP22158491.5A patent/EP4062928A3/en active Pending
- 2011-02-03 SI SI201131589T patent/SI3025728T1/sl unknown
- 2011-02-03 CN CN201710117140.0A patent/CN106834261B/zh active Active
- 2011-02-03 CN CN2011800090746A patent/CN102753566A/zh active Pending
- 2011-02-03 EP EP18187522.0A patent/EP3479842A3/en not_active Withdrawn
- 2011-02-03 CA CA2782444A patent/CA2782444C/en active Active
- 2011-02-03 ES ES15202466T patent/ES2690542T3/es active Active
- 2011-02-03 PL PL15202466T patent/PL3025728T3/pl unknown
- 2011-02-03 EP EP15202466.7A patent/EP3025728B1/en active Active
- 2011-02-03 WO PCT/US2011/023534 patent/WO2011097335A2/en not_active Ceased
- 2011-02-03 DK DK15202466.7T patent/DK3025728T3/en active
- 2011-02-03 HU HUE15202466A patent/HUE039516T2/hu unknown
- 2011-02-03 AU AU2011212929A patent/AU2011212929B2/en active Active
- 2011-02-03 EP EP11740323.8A patent/EP2531209B1/en active Active
- 2011-02-03 US US13/576,625 patent/US20130039898A1/en not_active Abandoned
- 2011-02-03 JP JP2012552071A patent/JP5828844B2/ja active Active
- 2011-02-03 LT LTEP15202466.7T patent/LT3025728T/lt unknown
- 2011-02-03 PT PT15202466T patent/PT3025728T/pt unknown
-
2012
- 2012-07-24 IL IL221099A patent/IL221099B/en active IP Right Grant
-
2016
- 2016-04-15 US US15/130,694 patent/US10221408B2/en active Active
- 2016-11-30 HK HK16113671.1A patent/HK1225299B/en unknown
-
2018
- 2018-02-08 IL IL257437A patent/IL257437B/en active IP Right Grant
- 2018-10-04 HR HRP20181602TT patent/HRP20181602T1/hr unknown
- 2018-10-17 CY CY181101068T patent/CY1120768T1/el unknown
-
2019
- 2019-01-11 US US16/246,300 patent/US11505790B2/en active Active
-
2022
- 2022-10-19 US US18/047,824 patent/US20240035013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518893A5 (https=) | ||
| JP6925688B2 (ja) | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン | |
| US9925277B2 (en) | Polynucleotide compositions containing amino acids | |
| ES2922760T3 (es) | Vacunas de virus respiratorios | |
| US10023626B2 (en) | Polynucleotides encoding immune modulating polypeptides | |
| JP2022122923A (ja) | 腫瘍学関連タンパク質およびペプチドの産生のための修飾ポリヌクレオチド | |
| WO2016022914A1 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| US20160194625A1 (en) | Chimeric polynucleotides | |
| JP6847664B2 (ja) | Ｐ９７−ポリヌクレオチド複合体 | |
| HRP20151268T1 (hr) | Pripravci prokariotske fenilalanin amonijak liaze i postupci upotrebe navedenog pripravka | |
| ES2919552T3 (es) | Procedimientos de utilización de polinucleotidos codificadores de ligando ox40 | |
| JP2010536759A5 (https=) | ||
| WO2015085318A2 (en) | Targeted adaptive vaccines | |
| EP4218787A2 (en) | Peptides for treating muscle atrophy | |
| Jiang et al. | Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum | |
| JP4232866B2 (ja) | 細胞障害抑制剤 | |
| US20240100152A1 (en) | Modified polynucleotides encoding the sars-cov-2 spike protein for safer designs of coronavirus vaccines | |
| US20250101061A1 (en) | Upregulation of ferritin heavy chain 1 expression | |
| JP6484839B2 (ja) | 新規ペプチド及びその用途 | |
| AU2017218918B2 (en) | Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders | |
| CN115776909A (zh) | 皮下端粒酶抑制剂组合物及其使用方法 | |
| US20170224773A1 (en) | Pharmaceutical composition for treating and/or preventing esophageal stenosis | |
| HK40090280A (zh) | 皮下端粒酶抑制剂组合物及其使用方法 | |
| O'Brien | OP28 Novel agents for ALL | |
| MXPA06007734A (es) | Agente preventivo para carcinogenesis de cancer de higado que contiene un compuesto basado en quinona como ingrediente activo. |